Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zimmer Biomet Holdings (GB:0QQD)
LSE:0QQD
RESEARCH TOOLSreports
Zimmer Biomet Holdings (0QQD) Share Price & Analysis
0 Followers
0QQD Stock Chart & Stats
Day’s RangeCHF114 - CHF114
52-Week Range― - ―
Previous CloseCHF114
Volume0.00
Average Volume (3M)N/A
Market Cap
$22.39B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
CHF1.72Last Dividend Ex-Date
Mar 27, 2024Dividend Yield0.8%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF124.75Price Target Upside9.43% Upside
Rating ConsensusHold
Number of Analyst Covering18
Zimmer Biomet Holdings News
Bulls Say, Bears Say
Bulls Say
Innovative TechnologyThe FDA's 510(k) clearance of the ROSA Shoulder System, as the world's first robotic surgery system for shoulder replacement, marks a significant technological advancement and could lead to increased market share for ZBH.
Market IntroductionWith the full launch of Persona IQ targeted for 2024, ZBH outlines a strategic plan indicating potential for increased product availability and market growth.
Product ImprovementFDA clearance of the shorter tibial stem for the ZBH Persona IQ smart knee implant suggests improved acceptance by patients and physicians, offering a size similar to standard tibial extensions.
Bears Say
Earnings Growth RiskZBH seems likely to pursue M&A which could be dilutive and result in another headwind to earnings growth.
Financial LeverageHigh net debt of $6,810 million suggests significant financial leverage.
Guidance ConcernsInvestors are concerned that the revenue guidance might be too high and leave little room for beats/raises.
---
Options Prices
Currently, No data available
---
Ownership Overview
35.10% Insiders
36.47% Mutual Funds
27.70% Other Institutional Investors
0.73% Public Companies and
Individual Investors
0QQD FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
Currently, no data Available
What is Zimmer Biomet Holdings’s market cap?
Currently, no data Available
When is Zimmer Biomet Holdings’s upcoming earnings report date?
Zimmer Biomet Holdings’s upcoming earnings report date is May 02, 2024 which is tomorrow.
How were Zimmer Biomet Holdings’s earnings last quarter?
Zimmer Biomet Holdings released its earnings results on Feb 08, 2024. The company reported CHF2.024 earnings per share for the quarter, beating the consensus estimate of CHF1.982 by CHF0.042.
Is Zimmer Biomet Holdings overvalued?
According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued.
Does Zimmer Biomet Holdings pay dividends?
Zimmer Biomet Holdings pays a Quarterly dividend of CHF0.22 which represents an annual dividend yield of 0.8%. See more information on Zimmer Biomet Holdings dividends here
What is Zimmer Biomet Holdings’s EPS estimate?
Zimmer Biomet Holdings’s EPS estimate is CHF1.72.
How many shares outstanding does Zimmer Biomet Holdings have?
Currently, no data Available
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Zimmer Biomet Holdings reported an EPS of CHF2.024 in its last earnings report, beating expectations of CHF1.982. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
Among the largest hedge funds holding Zimmer Biomet Holdings’s share is Dodge & Cox. It holds Zimmer Biomet Holdings’s shares valued at 1B.
---
Zimmer Biomet Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF124.75 (9.43% Upside)
CHF124.75 (9.43% Upside)
Blogger Sentiment
Bullish
GB:0QQD Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.44%
12-Months-Change
Fundamentals
Return on Equity
8.36%
Trailing 12-Months
Asset Growth
2.05%
Trailing 12-Months
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.
---
0QQD Earnings Call
Q4 2024
0:00 / 0:00
---
0QQD Net sales Breakdown
41.09% Knees
26.60% Hips
23.70% S.E.T
8.60% Other
---
0QQD Stock 12 Months Forecast
Average Price Target
CHF124.75
▲(9.43% Upside)
Technical Analysis
Best Analysts Covering 0QQD
1 Year
1 Year Success Rate
30/42 ratings generated profit
1 Year Average Return
+6.75%
assigned a buy rating 8 days ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +6.75% per trade.
---